ZBIO
Zenas Biopharma Inc
NASDAQ · Biotechnology
$21.80
+0.79 (+3.76%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 20.69M | 140.52M | 130.81M | 124.82M |
| Net Income | -649,730,155 | -116,113 | -126,311 | -113,132 |
| EPS | — | — | — | — |
| Profit Margin | -3,139.8% | -0.1% | -0.1% | -0.1% |
| Rev Growth | — | -3.7% | +16.0% | -9.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 299.15M | 339.29M | 361.86M |
| Total Equity | — | 337.93M | 370.10M | 341.01M |
| D/E Ratio | — | 0.89 | 0.92 | 1.06 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -647,386,669 | -178,287 | -168,053 | -162,378 |
| Free Cash Flow | — | -139,366 | -118,293 | -114,579 |